Alfresa (ARHCF)

What Moves the Stock

1. 01Japanese government drug pricing revisions (biennial NHI reimbursement rate cuts typically 2-8%)
2. 02Generic drug penetration rates in Japan (currently ~80% by volume, ~45% by value vs 90%+ in US)
3. 03Hospital consolidation trends and group purchasing organization dynamics
4. 04Pharmaceutical manufacturer inventory management and direct-to-pharmacy initiatives
5. 05Yen exchange rate movements affecting imported drug costs and margins
6. 06Prescription pharmaceutical distribution (~75-80% of revenue) - wholesale margins on branded and generic drugs
7. 07Medical device and equipment distribution (~15-20%) - surgical instruments, diagnostic equipment, hospital supplies
8. 08OTC medications and consumer health products (~5%) - retail pharmacy channel

ARHCF Chart

My Notes

• value - The stock trades at 0.2x sales and 1.0x book value, attracting deep value investors seeking defensive exposure to Japan's healthcare…
• Low direct impact as Debt/Equity is only 0.06, minimizing financing cost sensitivity.
• Watch on earnings: Japanese Ministry of Health biennial drug price revision announcements (next major revision April 2026), Generic drug adoption rates and biosimilar penetration in Japan, USD/JPY exchange rate (DEXJPUS) affecting imported pharmaceutical costs.